Switch theme
Sign up to access all valuation multiples
Lavipharm SA develops, manufactures, markets and distributes pharmaceutical, cosmetic and consumer health products in Greece and internationally. The company's product portfolio includes safe and effective therapeutic solutions that meet consumer' needs for health and wellbeing. Its main product categories are Cardiology, Oncology, Urology, Neurology, Psychiatry, General Medicine, Self- Treatment and Dermocosmetic care.
1911
307
LTM Revenue n/a
LTM EBITDA n/a
$161M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Lavipharm has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Lavipharm achieved revenue of $54.7M and an EBITDA of $10.6M.
Lavipharm expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Lavipharm valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $49.4M | $54.7M | XXX | XXX | XXX |
| Gross Profit | $17.1M | $19.3M | XXX | XXX | XXX |
| Gross Margin | 35% | 35% | XXX | XXX | XXX |
| EBITDA | $6.0M | $10.6M | XXX | XXX | XXX |
| EBITDA Margin | 12% | 19% | XXX | XXX | XXX |
| Net Profit | $1.9M | $0.9M | XXX | XXX | XXX |
| Net Margin | 4% | 2% | XXX | XXX | XXX |
| Net Debt | $25.4M | $7.9M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Lavipharm's stock price is EUR 1 (or $1).
Lavipharm has current market cap of EUR 127M (or $137M), and EV of EUR 150M (or $161M).
See Lavipharm trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $161M | $137M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Lavipharm has market cap of $137M and EV of $161M.
Lavipharm's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Lavipharm's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Lavipharm and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $161M | XXX | XXX | XXX |
| EV/Revenue | 2.9x | XXX | XXX | XXX |
| EV/EBITDA | 15.2x | XXX | XXX | XXX |
| P/E | 68.0x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -39.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpLavipharm's NTM/LTM revenue growth is n/a
Lavipharm's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Over next 12 months, Lavipharm's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Lavipharm's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Lavipharm and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 11% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 19% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 77% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.2M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 5% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 1% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 37% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Lavipharm acquired XXX companies to date.
Last acquisition by Lavipharm was XXXXXXXX, XXXXX XXXXX XXXXXX . Lavipharm acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Lavipharm founded? | Lavipharm was founded in 1911. |
| Where is Lavipharm headquartered? | Lavipharm is headquartered in Greece. |
| How many employees does Lavipharm have? | As of today, Lavipharm has 307 employees. |
| Is Lavipharm publicy listed? | Yes, Lavipharm is a public company listed on ATH. |
| What is the stock symbol of Lavipharm? | Lavipharm trades under LAVI ticker. |
| When did Lavipharm go public? | Lavipharm went public in 1995. |
| Who are competitors of Lavipharm? | Similar companies to Lavipharm include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Lavipharm? | Lavipharm's current market cap is $137M |
| What is the current revenue growth of Lavipharm? | Lavipharm revenue growth between 2023 and 2024 was 11%. |
| Is Lavipharm profitable? | Yes, Lavipharm is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
